2.Ovarian cancer risk reduction through opportunistic salpingectomy.
Journal of Gynecologic Oncology 2015;26(2):83-86
No abstract available.
Cost-Benefit Analysis
;
*Elective Surgical Procedures/economics/utilization
;
Fallopian Tubes/surgery
;
Female
;
Humans
;
Hysterectomy/economics/methods/utilization
;
Incidence
;
Ovarian Neoplasms/economics/epidemiology/*prevention & control
;
*Risk Reduction Behavior
;
Salpingectomy/economics/*utilization
;
Sterilization, Tubal/economics/utilization
3.Improving survival after endometrial cancer: the big picture.
Journal of Gynecologic Oncology 2015;26(3):227-231
To improve survival in women with endometrial cancer, we need to look at the "big picture" beyond initial treatment. Although the majority of women will be diagnosed with early stage disease and are cured with surgery alone, there is a subgroup of women with advanced and high-risk early stage disease whose life expectancy may be prolonged with the addition of chemotherapy. Immunohistochemistry will help to identify those women with Lynch syndrome who will benefit from more frequent colorectal cancer surveillance and genetic counseling. If they happen to be diagnosed with colorectal cancer, this information has an important therapeutic implication. And finally, because the majority of women will survive their diagnosis of endometrial cancer, they remain at risk for breast and colorectal cancer, so these women should be counselled about screening for these cancers. These three interventions will contribute to improving the overall survival of women with endometrial cancer.
Antineoplastic Agents/therapeutic use
;
Breast Neoplasms/diagnosis/mortality
;
Colorectal Neoplasms, Hereditary Nonpolyposis/diagnosis/mortality
;
Early Detection of Cancer
;
Endometrial Neoplasms/diagnosis/drug therapy/*mortality
;
Female
;
Humans
;
Life Expectancy
;
Risk Factors
4.Preoperative CA-125 in low-grade endometrial cancer: risk stratification and implications for treatment
Journal of Gynecologic Oncology 2019;30(5):e92-
No abstract available.
Endometrial Neoplasms
;
Female
5.Bone health after RRBSO among BRCA1/2 mutation carriers: a population-based study
Helena Abreu do VALLE ; Paramdeep KAUR ; Janice S. KWON ; Rona CHEIFETZ ; Lesa DAWSON ; Gillian E. HANLEY
Journal of Gynecologic Oncology 2022;33(4):e51-
Objective:
Examine the risks of fractures and osteoporosis after risk-reducing bilateral salpingo-oophorectomy (RRBSO) among women with BRCA1/2 mutations.
Methods:
In this retrospective population-based study in British Columbia, Canada, between 1996 to 2017, we compared risks of osteoporosis and fractures among women with BRCA1/2 mutations who underwent RRBSO before the age of 50 (n=329) with two age-matched groups without known mutations: 1) women who underwent bilateral oophorectomy (BO) (n=3,290); 2) women with intact ovaries who had hysterectomy or salpingectomy (n=3,290). Secondary outcomes were: having dual-energy X-ray absorptiometry (DEXA) scan, and bisphosphonates use.
Results:
The mean age at RRBSO was 42.4 years (range, 26–49) and the median follow-up for women with BRCA1/2 mutations was 6.9 years (range, 1.1–19.9). There was no increased hazard of fractures for women with BRCA1/2 mutations (adjusted hazard ratio [aHR]=0.80; 95% confidence interval [CI]=0.56–1.14 compared to women who had BO; aHR=1.02; 95% CI=0.65–1.61 compared to women with intact ovaries). Among women who had DEXA-scan, those with BRCA1/2 mutations had higher risk of osteoporosis (aHR=1.60; 95% CI=1.00–2.54 compared to women who had BO; aHR=2.49; 95% CI=1.44–4.28 compared to women with intact ovaries). Women with BRCA1/2 mutations were more likely to get DEXA-scan than either control groups, but only 46% of them were screened. Of the women with BRCA1/2 mutations diagnosed with osteoporosis, 36% received bisphosphonates.
Conclusion
Women with BRCA1/2 mutations had higher risk of osteoporosis after RRBSO, but were not at increased risk of fractures during our follow-up. Low rates of DEXA-scan and bisphosphonates use indicate we can improve prevention of bone loss.
6.Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma
Sarah Nicole HAMILTON ; Anna V. TINKER ; Janice KWON ; Peter LIM ; Iwa KONG ; Sona SIHRA ; Martin KOEBEL ; Cheng Han LEE
Journal of Gynecologic Oncology 2022;33(3):e25-
Objective:
Undifferentiated and dedifferentiated endometrial carcinoma is a rare type of uterine malignancy. This study assesses disease characteristics, treatment and survival outcomes in patients with undifferentiated and dedifferentiated endometrial carcinoma treated at BC Cancer.
Methods:
All patients diagnosed with undifferentiated and dedifferentiated endometrial carcinoma between 2000 and 2019 at BC Cancer were reviewed centrally. Clinical, pathologic, treatment and outcomes were reviewed retrospectively. The Kaplan-Meier method was used to evaluate overall survival (OS) and disease-free survival (DFS). Multivariable analysis was performed using Cox regression analysis.
Results:
Fifty-two patients were included, 33% had undifferentiated carcinoma and 67% dedifferentiated carcinoma. Sixty-nine percent of those who had mismatch repair (MMR) testing of their tumor had an abnormal profile. The 5-year DFS was 80% (95% confidence interval [CI]=71%–89%) for stage I/II, 29% (95% CI=28%–40%) for stage III and 10% (95% CI 1%–19%) for stage IV. The 5-year OS was 84% (95% CI=75%–92%) for stage I/II, 38% (95% CI=26%–50%) for stage III and 12% (95% CI=1%–24%) for stage IV. Multivariate analysis showed that receiving adjuvant chemotherapy, adjuvant radiotherapy, lower stage and better Eastern Cooperative Group performance status were associated with improved DFS (p<0.05).
Conclusion
Patients with stage I/II undifferentiated and dedifferentiated endometrial carcinoma had excellent survival outcomes, those with stage III/IV had worse outcomes, similar to previously reported. Adjuvant chemotherapy and radiotherapy were associated with improved DFS. MMR testing should be performed for these patients due to the high incidence of abnormal profiles.
7.Time for enhancing government-led primary prevention of cervical cancer
Kyung-Jin MIN ; Dong Hoon SUH ; Tsukasa BABA ; Xiaojun CHEN ; Jae-Weon KIM ; Yusuke KOBAYASHI ; Janice KWON ; Myong Cheol LIM ; Jung-Yun LEE ; Satoru NAGASE ; Jeong-Yeol PARK ; Siriwan TANGJITGAMOL ; Hidemichi WATARI
Journal of Gynecologic Oncology 2021;32(1):e12-
8.Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial
Janice S. KWON ; Helen MCTAGGART-COWAN ; Sarah E. FERGUSON ; Vanessa SAMOUËLIAN ; Eric LAMBAUDIE ; Frédéric GUYON ; John TIDY ; Karin WILLIAMSON ; Noreen GLEESON ; Cor de KROON ; Willemien van DRIEL ; Sven MAHNER ; Lars HANKER ; Frédéric GOFFIN ; Regina BERGER ; Brynhildur EYJÓLFSDÓTTIR ; Jae-Weon KIM ; Lori A. BROTTO ; Reka PATAKY ; Shirley S.T. YEUNG ; Kelvin K.W. CHAN ; Matthew C. CHEUNG ; Juliana UBI ; Dongsheng TU ; Lois E. SHEPHERD ; Marie PLANTE
Journal of Gynecologic Oncology 2024;35(6):e117-
Objective:
SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for quality of life and sexual health.The objective was to conduct a cost-effectiveness analysis comparing simple vs. radical hysterectomy for low-risk early-stage cervical cancer.
Methods:
Markov model compared the costs and benefits of simple vs. radical hysterectomy for early cervical cancer over a 5-year time horizon. Quality-adjusted life years (QALYs) were estimated from health utilities derived from EQ-5D-3L surveys. Sensitivity analyses accounted for uncertainty around key parameters. Monte Carlo simulation estimated complication numbers according to surgical procedure.
Results:
Simple hysterectomy was more effective and less costly than radical hysterectomy. Average overall costs were $11,022 and $12,533, and average gains were 3.56 and 3.54 QALYs for simple and radical hysterectomy, respectively. Baseline health utility scores were 0.81 and 0.83 for simple and radical hysterectomy, respectively. By year 3, these scores improved for simple hysterectomy (0.82) but not for radical hysterectomy (0.82). Assuming 800 early cervical cancer patients annually in Canada, the model estimated 3 vs. 82 patients with urinary retention, and 49 vs. 86 patients with urinary incontinence persisting 4 weeks after simple vs.radical hysterectomy, respectively. Results were most sensitive to variability in health utilities after surgery, but stable through wide ranges of costs and recurrence estimates.
Conclusion
Simple hysterectomy is less costly and more effective in terms of quality-adjusted life expectancy compared to radical hysterectomy for early cervical cancer.
9.Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial
Janice S. KWON ; Helen MCTAGGART-COWAN ; Sarah E. FERGUSON ; Vanessa SAMOUËLIAN ; Eric LAMBAUDIE ; Frédéric GUYON ; John TIDY ; Karin WILLIAMSON ; Noreen GLEESON ; Cor de KROON ; Willemien van DRIEL ; Sven MAHNER ; Lars HANKER ; Frédéric GOFFIN ; Regina BERGER ; Brynhildur EYJÓLFSDÓTTIR ; Jae-Weon KIM ; Lori A. BROTTO ; Reka PATAKY ; Shirley S.T. YEUNG ; Kelvin K.W. CHAN ; Matthew C. CHEUNG ; Juliana UBI ; Dongsheng TU ; Lois E. SHEPHERD ; Marie PLANTE
Journal of Gynecologic Oncology 2024;35(6):e117-
Objective:
SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for quality of life and sexual health.The objective was to conduct a cost-effectiveness analysis comparing simple vs. radical hysterectomy for low-risk early-stage cervical cancer.
Methods:
Markov model compared the costs and benefits of simple vs. radical hysterectomy for early cervical cancer over a 5-year time horizon. Quality-adjusted life years (QALYs) were estimated from health utilities derived from EQ-5D-3L surveys. Sensitivity analyses accounted for uncertainty around key parameters. Monte Carlo simulation estimated complication numbers according to surgical procedure.
Results:
Simple hysterectomy was more effective and less costly than radical hysterectomy. Average overall costs were $11,022 and $12,533, and average gains were 3.56 and 3.54 QALYs for simple and radical hysterectomy, respectively. Baseline health utility scores were 0.81 and 0.83 for simple and radical hysterectomy, respectively. By year 3, these scores improved for simple hysterectomy (0.82) but not for radical hysterectomy (0.82). Assuming 800 early cervical cancer patients annually in Canada, the model estimated 3 vs. 82 patients with urinary retention, and 49 vs. 86 patients with urinary incontinence persisting 4 weeks after simple vs.radical hysterectomy, respectively. Results were most sensitive to variability in health utilities after surgery, but stable through wide ranges of costs and recurrence estimates.
Conclusion
Simple hysterectomy is less costly and more effective in terms of quality-adjusted life expectancy compared to radical hysterectomy for early cervical cancer.
10.Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial
Janice S. KWON ; Helen MCTAGGART-COWAN ; Sarah E. FERGUSON ; Vanessa SAMOUËLIAN ; Eric LAMBAUDIE ; Frédéric GUYON ; John TIDY ; Karin WILLIAMSON ; Noreen GLEESON ; Cor de KROON ; Willemien van DRIEL ; Sven MAHNER ; Lars HANKER ; Frédéric GOFFIN ; Regina BERGER ; Brynhildur EYJÓLFSDÓTTIR ; Jae-Weon KIM ; Lori A. BROTTO ; Reka PATAKY ; Shirley S.T. YEUNG ; Kelvin K.W. CHAN ; Matthew C. CHEUNG ; Juliana UBI ; Dongsheng TU ; Lois E. SHEPHERD ; Marie PLANTE
Journal of Gynecologic Oncology 2024;35(6):e117-
Objective:
SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for quality of life and sexual health.The objective was to conduct a cost-effectiveness analysis comparing simple vs. radical hysterectomy for low-risk early-stage cervical cancer.
Methods:
Markov model compared the costs and benefits of simple vs. radical hysterectomy for early cervical cancer over a 5-year time horizon. Quality-adjusted life years (QALYs) were estimated from health utilities derived from EQ-5D-3L surveys. Sensitivity analyses accounted for uncertainty around key parameters. Monte Carlo simulation estimated complication numbers according to surgical procedure.
Results:
Simple hysterectomy was more effective and less costly than radical hysterectomy. Average overall costs were $11,022 and $12,533, and average gains were 3.56 and 3.54 QALYs for simple and radical hysterectomy, respectively. Baseline health utility scores were 0.81 and 0.83 for simple and radical hysterectomy, respectively. By year 3, these scores improved for simple hysterectomy (0.82) but not for radical hysterectomy (0.82). Assuming 800 early cervical cancer patients annually in Canada, the model estimated 3 vs. 82 patients with urinary retention, and 49 vs. 86 patients with urinary incontinence persisting 4 weeks after simple vs.radical hysterectomy, respectively. Results were most sensitive to variability in health utilities after surgery, but stable through wide ranges of costs and recurrence estimates.
Conclusion
Simple hysterectomy is less costly and more effective in terms of quality-adjusted life expectancy compared to radical hysterectomy for early cervical cancer.